Sesen Bio, Inc. (SESN): Price and Financial Metrics


Sesen Bio, Inc. (SESN): $3.93

0.20 (+5.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SESN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 500

in industry

SESN POWR Grades


  • SESN scores best on the Growth dimension, with a Growth rank ahead of 94.63% of US stocks.
  • SESN's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • SESN ranks lowest in Stability; there it ranks in the 4th percentile.

SESN Stock Summary

  • For SESN, its debt to operating expenses ratio is greater than that reported by just 0.53% of US equities we're observing.
  • SESN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 0.86% of US stocks.
  • The volatility of Sesen Bio Inc's share price is greater than that of 94.18% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to SESN, based on their financial statements, market capitalization, and price volatility, are GTH, FLXN, HZN, SBGI, and VVV.
  • SESN's SEC filings can be seen here. And to visit Sesen Bio Inc's official web site, go to www.sesenbio.com.

SESN Valuation Summary

  • SESN's EV/EBIT ratio is -4.7; this is 117.6% lower than that of the median Healthcare stock.
  • Over the past 91 months, SESN's price/sales ratio has gone down 76.5.
  • SESN's price/earnings ratio has moved up 1.7 over the prior 91 months.

Below are key valuation metrics over time for SESN.

Stock Date P/S P/B P/E EV/EBIT
SESN 2021-02-19 36.5 -24.8 -8.5 -9.2
SESN 2020-11-17 12.9 -8.8 -3.0 -2.6
SESN 2017-08-11 1.2 1.1 10.5 4.5
SESN 2016-05-20 22.7 1.8 -0.6 -0.3
SESN 2015-03-10 92.6 5.6 -6.0 -4.8
SESN 2014-03-19 180.1 -4.7 -11.0 -14.7

SESN Growth Metrics

  • The 3 year revenue growth rate now stands at -100%.
  • Its 2 year net cashflow from operations growth rate is now at -126.31%.
  • Its year over year net income to common stockholders growth rate is now at -79.35%.
Over the past 49 months, SESN's revenue has gone down $14,631,000.

The table below shows SESN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 15.546 -40.474 -119.473
2020-12-31 11.236 -30.837 -22.544
2020-09-30 11.236 -36.133 -48.098
2020-06-30 0 -39.104 -38.622
2020-03-31 0 -38.367 -66.613
2019-12-31 0 -37.521 -107.5

SESN Price Target

For more insight on analysts targets of SESN, see our SESN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.17 (Strong Buy)

SESN Stock Price Chart Interactive Chart >

Price chart for SESN

SESN Price/Volume Stats

Current price $3.93 52-week high $4.80
Prev. close $3.73 52-week low $0.91
Day low $3.76 Volume 5,116,884
Day high $3.98 Avg. volume 6,445,232
50-day MA $3.93 Dividend yield N/A
200-day MA $2.50 Market Cap 681.02M

Sesen Bio, Inc. (SESN) Company Bio


Sesen Bio (formerly Eleven Biotherapeutics, Inc.), a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts.


SESN Latest News Stream


Event/Time News Detail
Loading, please wait...

SESN Latest Social Stream


Loading social stream, please wait...

View Full SESN Social Stream

Latest SESN News From Around the Web

Below are the latest news stories about Sesen Bio Inc that investors may wish to consider to help them evaluate SESN as an investment opportunity.

Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US

CAMBRIDGE, Mass., July 26, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has completed its commercial build phase in preparation for the anticipated launch of Vicineum, if approved, in the US, and has advanced to the implementation phase that will focus on executing the Company’s commercial strategy for Vicineum. The Biologics License Application (BLA) for Vicineum,

Yahoo | July 26, 2021

Sesen Bio Announces New Appointments to its Board of Directors

CAMBRIDGE, Mass., July 21, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Dr. Peter K Honig, MPH, former Senior Vice President and Head of Global Regulatory Affairs and Group Head of Development China and Japan at Pfizer, and Dr. Michael A.S. Jewett, FRCSC, FACS, a practicing Oncologist and global Key Opinion Leader (KOL) to the Sesen Bio Board of Director

Yahoo | July 21, 2021

Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China

CAMBRIDGE, Mass., July 20, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and its partner in Greater China, Qilu Pharmaceutical, announced today that the first patient has been enrolled in China in the clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The milestone comes only four months after the Invest

Yahoo | July 20, 2021

Sesen Bio Announces Positive Outcome From Late-Cycle FDA Meeting For Vicineum Application

Sesen Bio Inc (NASDAQ: SESN) participated in a Late-Cycle Meeting with the FDA regarding the marketing application seeking approval for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The FDA confirmed that there is no Advisory Committee meeting planned at this time. No issues related to risk management have been identified to date. No post-marketing requirements, including a confirmatory trial, have been identified as necessary at this time. The Company believes the ap

Yahoo | July 14, 2021

Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™

CAMBRIDGE, Mass., July 14, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s Biologics License Application (BLA) for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) currently under Pr

Yahoo | July 14, 2021

Read More 'SESN' Stories Here

SESN Price Returns

1-mo -7.53%
3-mo 35.52%
6-mo 97.49%
1-year 277.88%
3-year 129.82%
5-year -1.50%
YTD 191.11%
2020 29.81%
2019 -26.76%
2018 75.09%
2017 -57.54%
2016 -36.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8558 seconds.